Post-earnings recap
Reported
Tue, Aug 9, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Axsome Therapeutics reported a loss per share of $0.36, but did not disclose revenue figures. The stock fell by 1.17% following the report, likely due to the lack of guidance and clarity on future performance. Investors may be concerned about the company's path forward without specific targets or revenue updates.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook, emphasizing the importance of their clinical trials. They did not provide specific guidance for future performance.
Management did not provide specific guidance for future quarters.
The company is focusing on ongoing clinical trials and product development.